The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
The group’s point-of-care Car-T push looks to have stalled.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.